Clinical Trials Logo

Clinical Trial Summary

IGHN2 is an international, multicenter, double blind, randomized controlled trial aimed at assessing the efficacy on organ dysfunctions of Intravenous Immunoglobulins (IVIG) treatment in the acute phase of streptococcal or staphylococcal toxic shock syndrome in children.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02899702
Study type Interventional
Source Hospices Civils de Lyon
Contact
Status Withdrawn
Phase Phase 4
Start date September 2020
Completion date September 2024

See also
  Status Clinical Trial Phase
Completed NCT00770341 - A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002) Phase 3
Completed NCT00352612 - Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections Phase 4
Completed NCT00279864 - The Utility of Levofloxacin-Rifampin in the Therapy of Prosthetic Joint Infection N/A
Completed NCT00735839 - V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED) Phase 1
Completed NCT00814151 - MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial N/A
Completed NCT02812446 - Staphylokinase and ABO Group Phenotype: New Players in Staphylococcus Aureus Implant-associated Infections Development N/A
Completed NCT00846105 - Efficacy Study of Rapid Test to Prevent Hospital Transmission of Methicillin-Resistant Staphylococcus Aureus (MRSA) N/A
Completed NCT02284555 - Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment) Phase 4
Completed NCT01592214 - Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73 Phase 1
Completed NCT01827358 - Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants Phase 2
Completed NCT00729937 - Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA" Phase 2/Phase 3
Completed NCT00730028 - Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus Phase 2